2024-03-29T12:19:49Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/51192023-10-05T08:26:04Zcom_20.500.12105_2145com_20.500.12105_2051com_20.500.12105_2144col_20.500.12105_2146
Repisalud
author
Bobi, Joaquim
author
Solanes, Nuria
author
Fernandez-Jimenez, Rodrigo
author
Galan-Arriola, Carlos
author
Dantas, Ana Paula
author
Fernandez-Friera, Leticia
author
Galvez-Monton, Carolina
author
Rigol-Monzo, Elisabet
author
Aguero, Jaume
author
Ramirez, Jose
author
Roque, Merce
author
Bayes-Genis, Antoni
author
Sanchez-Gonzalez, Javier
author
Garcia-Alvarez, Ana
author
Sabaté, Manel
author
Roura, Santiago
author
Ibáñez, Borja
author
Rigol, Montserrat
funder
Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
funder
Instituto de Salud Carlos III
funder
Ministerio de Educación y Ciencia (España)
funder
Fundación Jesús Serra
funder
Fundación Interhospitalaria de Investigación Cardiovascular
funder
Medis Medical Imaging
funder
Ministerio de Economía, Industria y Competitividad (España)
funder
Fundación ProCNIC
funder
Fundación La Caixa
funder
Government of Catalonia (España)
funder
Fundación La Marató TV3
2017-10-20T10:23:12Z
2017-10-20T10:23:12Z
2017
J Am Heart Assoc. 2017; 6(5):e005771
2047-9980
http://hdl.handle.net/20.500.12105/5119
28468789
10.1161/JAHA.117.005771
Journal of the American Heart Association
Background-Autologous adipose tissue-derived mesenchymal stem cells (ATMSCs) therapy is a promising strategy to improve post-myocardial infarction outcomes. In a porcine model of acute myocardial infarction, we studied the long-term effects and the mechanisms involved in allogeneic ATMSCs administration on myocardial performance. Methods and Results-Thirty-eight pigs underwent 50 minutes of coronary occlusion; the study was completed in 33 pigs. After reperfusion, allogeneic ATMSCs or culture medium (vehicle) were intracoronarily administered. Follow-ups were performed at short (2 days after acute myocardial infarction vehicle-treated, n=10; ATMSCs-treated, n=9) or long term (60 days after acute myocardial infarction vehicle-treated, n=7; ATMSCs-treated, n=7). At short term, infarcted myocardium analysis showed reduced apoptosis in the ATMSCs-treated animals (48.6 +/- 6\% versus 55.9 +/- 5.7\% in vehicle; P=0.017); enhancement of the reparative process with up-regulated vascular endothelial growth factor, granulocyte macrophage colony-stimulating factor, and stromal-derived factor-1 alpha gene expression; and increased M2 macrophages (67.2 +/- 10\% versus 54.7 +/- 10.2\% in vehicle; P=0.016). In long-term groups, increase in myocardial perfusion at the anterior infarct border was observed both on day-7 and day-60 cardiac magnetic resonance studies in ATMSCs-treated animals, compared to vehicle (87.9 +/- 28.7 versus 57.4 +/- 17.7 mL/min per gram at 7 days; P=0.034 and 99 +/- 22.6 versus 43.3 +/- 14.7 22.6 mL/min per gram at 60 days; P=0.0001, respectively). At day 60, higher vascular density was detected at the border zone in the ATMSCs-treated animals (118 +/- 18 versus 92.4 +/- 24.3 vessels/mm(2) in vehicle; P=0.045). Cardiac magnetic resonance-measured left ventricular ejection fraction of left ventricular volumes was not different between groups at any time point. Conclusions-In this porcine acute myocardial infarction model, allogeneic ATMSCs-based therapy was associated with increased cardioprotective and reparative mechanisms and with better cardiac magnetic resonance-measured perfusion. No effect on left ventricular volumes or ejection fraction was observed.
eng
adipose tissue-derived mesenchymal stem cells
allogeneic origin
myocardial infarction
myocardial perfusion
vascular density
RANDOMIZED PHASE-1 TRIAL
CARDIAC-FUNCTION
ISCHEMIC CARDIOMYOPATHY
PROMOTE ANGIOGENESIS
PROGENITOR CELLS
HEART-FAILURE
PORCINE MODEL
DISEASE
THERAPY
ISCHEMIA/REPERFUSION
Intracoronary Administration of Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Improves Myocardial Perfusion But Not Left Ventricle Function, in a Translational Model of Acute Myocardial Infarction
journal article
URL
https://repisalud.isciii.es/bitstream/20.500.12105/5119/1/IntracoronaryAdministrationOfAllogeneic_2017
File
MD5
df1784b6f7f20e2404e8930915ee10ba
2882242
application/pdf
IntracoronaryAdministrationOfAllogeneic_2017
URL
https://repisalud.isciii.es/bitstream/20.500.12105/5119/10/IntracoronaryAdministrationOfAllogeneic_2017.txt
File
MD5
06bb5b7774929bfd6a78b444c2953c83
72377
text/plain
IntracoronaryAdministrationOfAllogeneic_2017.txt
URL
https://repisalud.isciii.es/bitstream/20.500.12105/5119/16/IntracoronaryAdministrationOfAllogeneic_2017.txt
File
MD5
06bb5b7774929bfd6a78b444c2953c83
72377
text/plain
IntracoronaryAdministrationOfAllogeneic_2017.txt